JP2014515036A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515036A5 JP2014515036A5 JP2014510798A JP2014510798A JP2014515036A5 JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5 JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014510798 A JP2014510798 A JP 2014510798A JP 2014515036 A5 JP2014515036 A5 JP 2014515036A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- maytansinoid immunoconjugate
- maytansinoid
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 39
- 229940127121 immunoconjugate Drugs 0.000 claims 35
- 208000024891 symptom Diseases 0.000 claims 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 11
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 7
- 239000005022 packaging material Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000036210 malignancy Effects 0.000 claims 5
- 230000002411 adverse Effects 0.000 claims 4
- 231100000419 toxicity Toxicity 0.000 claims 4
- 230000001988 toxicity Effects 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 206010061137 Ocular toxicity Diseases 0.000 claims 1
- 206010044245 Toxic optic neuropathy Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000000564 macroglobulinemia Diseases 0.000 claims 1
- 231100000327 ocular toxicity Toxicity 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290232A EP2524929A1 (en) | 2011-05-17 | 2011-05-17 | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP11290232.5 | 2011-05-17 | ||
| PCT/EP2012/059141 WO2012156455A1 (en) | 2011-05-17 | 2012-05-16 | Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Division JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515036A JP2014515036A (ja) | 2014-06-26 |
| JP2014515036A5 true JP2014515036A5 (cg-RX-API-DMAC7.html) | 2014-08-07 |
| JP6050328B2 JP6050328B2 (ja) | 2016-12-21 |
Family
ID=46085972
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014510798A Expired - Fee Related JP6050328B2 (ja) | 2011-05-17 | 2012-05-16 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016226407A Expired - Fee Related JP6181273B2 (ja) | 2011-05-17 | 2016-11-22 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2017138852A Pending JP2018021020A (ja) | 2011-05-17 | 2017-07-18 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
| JP2019087962A Pending JP2019142961A (ja) | 2011-05-17 | 2019-05-08 | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 |
Country Status (30)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US9637547B2 (en) | 2013-08-30 | 2017-05-02 | Immunogen, Inc. | Monoclonal antibodies for detection of folate receptor 1 |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| WO2016180941A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| CA2986175A1 (en) | 2015-05-26 | 2016-12-01 | Morphosys Ag | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| AU2016311136B2 (en) | 2015-08-21 | 2022-02-17 | Incyte Corporation | Combinations and uses thereof |
| IL257531B2 (en) | 2015-09-17 | 2023-04-01 | Immunogen Inc | Medicinal compositions containing anti-folr1 immunoconjugates |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| MA45124B1 (fr) | 2016-05-30 | 2021-05-31 | Morphosys Ag | Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients |
| CN115998859A (zh) | 2016-06-27 | 2023-04-25 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| MX2019012462A (es) * | 2017-04-20 | 2020-07-27 | Adc Therapeutics Sa | Terapia combinada. |
| BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
| AU2018336520B2 (en) | 2017-09-21 | 2025-03-27 | WuXi Biologics Ireland Limited | Novel anti-CD19 antibodies |
| MA50185A (fr) | 2017-09-22 | 2020-07-29 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques cd3/cd19 bispécifiques |
| CN111587125A (zh) | 2018-01-12 | 2020-08-25 | 伊缪诺金公司 | 抗体药物缀合、纯化和调配的方法 |
| EP3958977B1 (en) | 2019-04-26 | 2023-09-13 | ImmunoGen, Inc. | Camptothecin derivatives |
| MX2021013101A (es) | 2019-05-03 | 2022-01-04 | Morphosys Ag | Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk. |
| US20210130461A1 (en) | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| IL317199A (en) | 2019-10-31 | 2025-01-01 | Morphosys Ag | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| CA3153636A1 (en) * | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN111303286B (zh) * | 2019-12-05 | 2022-05-20 | 常州费洛斯药业科技有限公司 | 一种anti-CD19的全人源抗体或抗体片段及其嵌合抗原受体和应用 |
| CN115956088A (zh) | 2020-06-22 | 2023-04-11 | 莫佛塞斯公司 | 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法 |
| IL301865A (en) | 2020-10-06 | 2023-06-01 | Xencor Inc | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| JP2025528837A (ja) | 2022-08-17 | 2025-09-02 | インサイト・コーポレイション | 抗ｃｄ１９抗体及びｅｚｈ２モジュレーターを含む治療 |
| WO2025087382A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海先博生物科技有限公司 | 靶向cd19的嵌合抗原受体的治疗用途 |
| WO2025157132A1 (en) | 2024-01-23 | 2025-07-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2427858A1 (en) * | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| CR20170291A (es) | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinóides |
| CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| EP3360879A1 (en) * | 2009-02-05 | 2018-08-15 | ImmunoGen, Inc. | Benzodiazepine derivatives as cytotoxic agents |
| JP2012526079A (ja) * | 2009-05-06 | 2012-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体の使用 |
| RU2012120691A (ru) * | 2009-10-21 | 2013-11-27 | Иммьюноджен, Инк. | Новый режим дозирования и способ лечения |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| EP2550975A1 (en) * | 2011-07-29 | 2013-01-30 | Sanofi | Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab |
-
2011
- 2011-05-17 EP EP11290232A patent/EP2524929A1/en not_active Ceased
-
2012
- 2012-05-16 SG SG10201609729VA patent/SG10201609729VA/en unknown
- 2012-05-16 MX MX2013013455A patent/MX347019B/es active IP Right Grant
- 2012-05-16 KR KR1020137033076A patent/KR20140043388A/ko not_active Abandoned
- 2012-05-16 PE PE2013002503A patent/PE20141018A1/es not_active Application Discontinuation
- 2012-05-16 UA UAA201314732A patent/UA114401C2/uk unknown
- 2012-05-16 CA CA2835738A patent/CA2835738A1/en not_active Abandoned
- 2012-05-16 AR ARP120101724A patent/AR086412A1/es unknown
- 2012-05-16 CN CN201280023918.7A patent/CN103547596A/zh active Pending
- 2012-05-16 EA EA201391714A patent/EA028574B1/ru not_active IP Right Cessation
- 2012-05-16 US US14/117,806 patent/US9555126B2/en not_active Expired - Fee Related
- 2012-05-16 AU AU2012258254A patent/AU2012258254B2/en not_active Ceased
- 2012-05-16 PH PH1/2013/502305A patent/PH12013502305A1/en unknown
- 2012-05-16 WO PCT/EP2012/059141 patent/WO2012156455A1/en not_active Ceased
- 2012-05-16 MY MYPI2013004057A patent/MY163736A/en unknown
- 2012-05-16 EP EP12721529.1A patent/EP2710034A1/en not_active Withdrawn
- 2012-05-16 SG SG2013083407A patent/SG194894A1/en unknown
- 2012-05-16 BR BR112013029330A patent/BR112013029330A8/pt not_active IP Right Cessation
- 2012-05-16 JP JP2014510798A patent/JP6050328B2/ja not_active Expired - Fee Related
- 2012-05-16 CN CN201611022631.9A patent/CN107007840A/zh active Pending
- 2012-05-17 UY UY0001034077A patent/UY34077A/es not_active Application Discontinuation
- 2012-05-17 TW TW105134320A patent/TW201726167A/zh unknown
- 2012-05-17 TW TW101117628A patent/TWI601537B/zh not_active IP Right Cessation
- 2012-05-17 TW TW107102069A patent/TW201834687A/zh unknown
-
2013
- 2013-11-11 IL IL229380A patent/IL229380B/en active IP Right Grant
- 2013-11-12 TN TNP2013000468A patent/TN2013000468A1/fr unknown
- 2013-11-12 NI NI201300119A patent/NI201300119A/es unknown
- 2013-11-12 GT GT201300276A patent/GT201300276A/es unknown
- 2013-11-12 DO DO2013000260A patent/DOP2013000260A/es unknown
- 2013-11-13 CR CR20130593A patent/CR20130593A/es unknown
- 2013-11-14 CL CL2013003272A patent/CL2013003272A1/es unknown
- 2013-12-12 MA MA36558A patent/MA35180B1/fr unknown
- 2013-12-12 ZA ZA2013/09400A patent/ZA201309400B/en unknown
- 2013-12-16 CO CO13293559A patent/CO6821893A2/es unknown
- 2013-12-16 EC ECSP13013084 patent/ECSP13013084A/es unknown
-
2016
- 2016-07-21 AU AU2016206317A patent/AU2016206317A1/en not_active Abandoned
- 2016-11-22 JP JP2016226407A patent/JP6181273B2/ja not_active Expired - Fee Related
- 2016-12-16 US US15/381,266 patent/US20170196988A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017138852A patent/JP2018021020A/ja active Pending
- 2017-07-28 PH PH12017501368A patent/PH12017501368A1/en unknown
-
2018
- 2018-02-12 IL IL257475A patent/IL257475A/en unknown
- 2018-03-01 AU AU2018201504A patent/AU2018201504A1/en not_active Abandoned
- 2018-12-16 IL IL263728A patent/IL263728A/en unknown
-
2019
- 2019-05-08 JP JP2019087962A patent/JP2019142961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515036A5 (cg-RX-API-DMAC7.html) | ||
| Poletto et al. | Treatment strategies for patients with diffuse large B-cell lymphoma | |
| JP6181273B2 (ja) | Ｂ細胞悪性腫瘍の症状の治療のための抗ｃｄ１９メイタンシンノイドイムノコンジュゲート抗体の使用 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| TWI549690B (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2016531915A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500014A5 (cg-RX-API-DMAC7.html) | ||
| JP2014533279A5 (cg-RX-API-DMAC7.html) | ||
| KR20140019298A (ko) | Dlbcl의 치료 수단 및 방법 | |
| JP2016538318A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500822A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536112A (ja) | Ｔ細胞免疫療法のための組合せ及びその使用 | |
| JP2021501776A5 (cg-RX-API-DMAC7.html) | ||
| WO2017066583A1 (en) | A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use | |
| JP2020510039A5 (cg-RX-API-DMAC7.html) | ||
| JP2015517512A (ja) | Ｃｄ３７抗体の更なる薬剤との併用 | |
| EP2849784A1 (en) | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) | |
| JP2016525560A5 (cg-RX-API-DMAC7.html) | ||
| JP2024028865A (ja) | 抗ｃｄ１９抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム | |
| Anastasia et al. | Novel drugs in follicular lymphoma | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| JP2015516980A (ja) | Ｃｄ３７抗体とベンダムスチンとの併用 | |
| Doubek et al. | Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading? | |
| Stathis et al. | New agents for the treatment of lymphoma | |
| US20160106837A1 (en) | Combination of cd37 antibodies with chlorambucil |